• Pharmacokinetics and safety [ Time Frame: 31 Mar 2008 ] [ Designated as safety issue: Yes ]
  

• Progression free survival (PFS) [ Time Frame: 31 Mar 2008 ] [ Designated as safety issue: No ]
  
• Overall survival (OS) [ Time Frame: 31 Mar 2008 ] [ Designated as safety issue: No ]
  
• Time to Progression [ Time Frame: 31 Mar 2008 ] [ Designated as safety issue: No ]
  
• Disease Control Rate [ Time Frame: 31 Mar 2008 ] [ Designated as safety issue: No ]
  
• Overall Best Response [ Time Frame: 31 Mar 2008 ] [ Designated as safety issue: No ]
  
• Overall response duration [ Time Frame: 31 Mar 2008 ] [ Designated as safety issue: No ]
  
• Time to objective response [ Time Frame: 31 Mar 2008 ] [ Designated as safety issue: No ]
  
• Health related quality of life [ Time Frame: 31 Mar 2008 ] [ Designated as safety issue: No ]
  

Inclusion Criteria:

• Patients who have a life expectancy of at least 12 weeks
• Patients, who suffer from unresectable and/or metastatic, measurable RCC histologically or cytologically documented. Patients with rare subtypes of RCC such as pure papillary cell tumor, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors are excluded from study participation.
• Patients who have received not more than one prior systemic therapy for advanced disease which was completed at least 30 days prior to the first dose of study medication.
• Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumours (RECIST)
• Patients with "Intermediate" or "low" risk per the Motzer score
• Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1
• Adequate bone marrow, liver and renal function at screening as assessed by the following:
• Total bilirubin < 1.5 x the upper limit of normal.
• ALT and AST < 2.5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement of their cancer).

• Amylase and lipase < 1.5 x the upper limit of normal.

  • Serum creatinine < 2.0 x the upper limit of normal.
  • PT or INR and PTT < 1.5 x upper limit of normal

Exclusion Criteria:

• Previous or concurrent cancer that is distinct in primary sit or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, adequately treated basal cell carcinoma, superficial bladder tumors [Ta, Tis and T1] or any cancer curatively treated > 3 years prior to study entry)
• Patients who completed their prior systemic treatment regimen less than 30 days
• Cardiac arrhythmias requiring anti-arrhythmic (excluding beta blockers or digoxin), symptomatic coronary artery disease or ischemia
• Active clinically serious bacterial or fungal infections
• Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C requiring current interferon treatment
• Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has a negative imaging studies within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry.
• Patients with evidence or history of bleeding diathesis.
• Patients with seizure disorder requiring medication
• History of organ allograft
• Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
• Pregnant or breast-feeding patients.

Excluded concomitant medications:

• Concurrent anti-cancer chemotherapy, immunotherapy, or hormonal therapy except Bisphosphonates
• Radiotherapy during study or within 3 weeks of start of study drug.
• Biological response modifiers, such as G-CSF or GM-CSF, within 3 weeks prior to study entry or during study
• Significant surgery within 4 weeks prior to start of study drug
• Autologous bone marrow transplant or stem cell rescue within 4 months of study
• Investigational drug therapy during or within 4 weeks prior to first drug administration and during the study
• St John's Wort
• Xiao Chai Hu Tang
• Prior and concomitant use of Bevacizumab, and all other drugs (investigational or licensed) that target VEGF/VEGF-Receptors, Raf-kinase inhibitors (RKI), MEK or Farnesyl transferase inhibitors